The Effect of Curcumin on Iron Overload in Patients with Beta-Thalassemia Intermedia

Saeidnia, Mohammadreza; Fazeli, Pooria; Erfani, Mehran; Nowrouzi-Sohrabi, Peyman; Tamaddon, Gholamhossein; Karimi, Mehran

doi:10.7754/clin.lab.2021.210629

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our investigation, after 6 months of assessment, neither the serum ferritin level nor the amount of iron overload determined by T2MRI significantly decreased. In contrast, after 3 months of consuming 1,500 mg of curcumin daily, serum iron, transferrin saturation, and ferritin levels decreased significantly compared to placebo in several investigations (Ghone et al, 2008;Weeraphan et al, 2013;Saeidnia et al, 2022). Additionally, a decline in free iron index and serum non-transferrin binding iron was observed in another study, while a decline in total iron binding capacity and ferritin levels was not (Mohammadi et al, 2018).…”

Section: Discussionmentioning

confidence: 93%

“…Today, curcumin present in turmeric has been considered due to its cancer-preventive features, antioxidant and anti-inflammatory properties ( Milani et al, 2017 ; Nasseri et al, 2018 ). Several studies have shown that curcumin may form complexes with various metal ions, especially iron, which is very dangerous for the heart and liver due to the active polyphenol structure in curcumin, which exhibits iron chelating properties ( Lee et al, 2016 ; Saeidnia et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major: a double‐blind randomized controlled clinical trial

Eghbali,

Nourigheimasi,

Ghasemi

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Curcumin present in turmeric has been considered due to its cancer-preventive features, antioxidant and anti-inflammatory properties. This double-blind, randomized, controlled clinical trial with a reasonable sample size and longer intervention period was conducted to investigate how oral curcumin affected cardiac and hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major.Method: This clinical trial study was conducted on 171 patients over 5 years old. The subjects were randomly divided into a curcumin-treatment group and a placebo group to receive either curcumin capsules twice daily or placebo for 6 months. Patients were examined once a month for 6 months to receive capsules and measure the levels of alanine aminotransferase (ALT), aspartate transferase (AST), alkaline phosphatase (ALP), direct and total bilirubin, ferritin and cardiac and hepatic T2*MRI.Result: There was a significant decrease in levels of AST, ALT, ALP, and bilirubin (direct and total) in the curcumin group compared with the placebo group by the end of the study (p < 0.05). The levels of serum ferritin remained unchanged in both groups at the end of the follow‐up period (p > 0.05). No significant differences were observed between the curcumin and placebo groups at baseline values or at the end of the study of cardiac and hepatic T2*MRI and serum magnesium.Conclusion: Administration of curcumin has some beneficial effects on liver function by reducing liver enzymes in patients with beta-thalassemia major.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major: a double‐blind randomized controlled clinical trial

Eghbali,

Nourigheimasi,

Ghasemi

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In a permuted block randomized study, curcuminoids (500 and 1000 mg/day) reduced the hypercoagulability marker D-dimer, NTBI, ROS, MDA, D-dimer, hs-CRP, TNF-α, TGF-β1, IFN-γ, IL-1β, IL-6, IL-8, serum iron, and transferrin saturation in β-thalassemia . Recently, a randomized, double-blind study showed that curcumin supplementation reduced serum levels of iron, ferritin, and transferrin when compared to placebo in patients with β-thalassemia intermedia …”

Section: Clinical Trials Of Turmeric and Curcuminmentioning

confidence: 99%

“…499 Recently, a randomized, double-blind study showed that curcumin supplementation reduced serum levels of iron, ferritin, and transferrin when compared to placebo in patients with βthalassemia intermedia. 500 4.2.9. Turmeric and Curcumin in Kidney Diseases.…”

Section: Turmeric and Curcumin In Inheritedmentioning

confidence: 99%

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Kunnumakkara

Hegde

Dey

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Turmeric (Curcuma longa) has been used for thousands of years for the prevention and treatment of various chronic diseases. Curcumin is just one of >200 ingredients in turmeric. Almost 7000 scientific papers on turmeric and almost 20,000 on curcumin have been published in PubMed. Scientific reports based on cell culture or animal studies are often not reproducible in humans. Therefore, human clinical trials are the best indicators for the prevention and treatment of a disease using a given agent/drug. Herein, we conducted an extensive literature survey on PubMed and Scopus following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The keywords "turmeric and clinical trials" and "curcumin and clinical trials" were considered for data mining. A total of 148 references were found to be relevant for the key term "turmeric and clinical trials", of which 70 were common in both PubMed and Scopus, 44 were unique to PubMed, and 34 were unique to Scopus. Similarly, for the search term "curcumin and clinical trials", 440 references were found to be relevant, of which 70 were unique to PubMed, 110 were unique to Scopus, and 260 were common to both databases. These studies show that the golden spice has enormous health and medicinal benefits for humans. This Review will extract and summarize the lessons learned about turmeric and curcumin in the prevention and treatment of chronic diseases based on clinical trials.

show abstract

“…It is reasonable to assume that antioxidant therapy will be beneficial to iron overloaded thalassemia patients. Encouraging results from several randomized controlled trials have shown that natural antioxidants such as green tea and curcumin may be helpful; however, studies with a longer duration are needed to assess the long-term effects [ 78 , 79 , 80 , 81 ]. In 2021, according to the Thalassemia International Federation guidelines for the management of TDT, a diet rich in foods high in vitamin E, such as plant oils, eggs, nuts, and cereals, is recommended.…”

Section: Managementmentioning

confidence: 99%

Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies

Lin,

Hsu,

Lee

et al. 2023

IJMS

View full text Add to dashboard Cite

Thalassemia is a heterogeneous congenital hemoglobinopathy common in the Mediterranean region, Middle East, Indian subcontinent, and Southeast Asia with increasing incidence in Northern Europe and North America due to immigration. Iron overloading is one of the major long-term complications in patients with thalassemia and can lead to organ damage and carcinogenesis. Hepatocellular carcinoma (HCC) is one of the most common malignancies in both transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). The incidence of HCC in patients with thalassemia has increased over time, as better chelation therapy confers a sufficiently long lifespan for the development of HCC. The mechanisms of iron-overloading-associated HCC development include the increased reactive oxygen species (ROS), inflammation cytokines, dysregulated hepcidin, and ferroportin metabolism. The treatment of HCC in patients with thalassemia was basically similar to those in general population. However, due to the younger age of HCC onset in thalassemia, regular surveillance for HCC development is mandatory in TDT and NTDT. Other supplemental therapies and experiences of novel treatments for HCC in the thalassemia population were also reviewed in this article.

show abstract

The Effect of Curcumin on Iron Overload in Patients with Beta-Thalassemia Intermedia

Cited by 3 publications

References 0 publications

The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major: a double‐blind randomized controlled clinical trial

The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major: a double‐blind randomized controlled clinical trial

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies

Contact Info

Product

Resources

About